Epstein–Barr virus infection in patients after hematopoietic stem cells transplantation
Abstract
Epstein–Barr virus (EBV) is a member of herpes-viruses family. Now it is well-known, that it can be a cause of wide spectrum lymphoproliferative disoders. The given problem is especially serious after hematopoietic stem cells transplantation (HSCT); frequency of death linked to this complication can achieve 50–90 %. Risk factors for development of posttransplant lymphoproliferative syndromes (PTLS) are: using partially compatible graft, T-cell depletion, presence of severe acute graft-versus-host reaction (GVHD), using of antitymocytic globulin, etc. Severity of associated with EBV posttransplant complications and problems relate to absence of clear diagnostic algorithm, PTLS prophylactic and therapy schedule are argument for necessity of the further studies.
About the Authors
D. N. Balashov
Federal Research Center of Pediatric Hematology, Oncology and Immunology; Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
L. N. Shelikhova
Federal Research Center of Pediatric Hematology, Oncology and Immunology; Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
A. A. Demushkina
Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
P. E. Trakhtman
Federal Research Center of Pediatric Hematology, Oncology and Immunology; Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
Ye. V. Skorobogatova
Federal Research Center of Pediatric Hematology, Oncology and Immunology; Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
D. V. Litvinov
Federal Research Center of Pediatric Hematology, Oncology and Immunology; Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
Ye. V. Raykina
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation
Russian Federation
Moscow
A. A. Maschan
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation
Russian Federation
Moscow
References
1. Babcock G. J., Decker L. L., Volk M., Thorley-Lawson D. A. EBV persistence in memory B cells in vivo. Immunity 1998; 9: 395–404.
2. Murray R. J., Kurilla M. G., Brooks J. M., Thomas W. A., Rowe M., Kieff E. et al. Identification of target antigens for the human cytotoxic T-cell response to Epstein–Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176: 157–68.
3. Khanna R., Burrows S. R. Role of cytotoxic T-lymphocytes in Epstein–Barr virus-associated diseases. Annu Rev Microbiol 2000; 54: 19–48.
4. Bacigalupo A. Antithymocyte globuline for prevention of graft-versus-host disease. Curr Opin Hematol 2005;12: 457–62.
5. Markasz L., Stuber G., Flaberg E., Jernberg A. G., Eksborg S., Olah E. et al. Cytotoxic drug sensitivity of Epstein–Barr virus transformed lymphoblastoid B-cells. BMC Cancer 2006; 6: 265.
6. Bower M. The management of lymphoma in the immunosuppressed patient. Best Pract Res Clin Haematol 2002; 15: 517–32.
7. Meijer E. and Cornelissen J. J. Epstein–Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients Current Opinion in Hematology 2008; 15: 576–85.
8. Juvonen E., Aalto S., Tarkkanen J. et al. Retrospective evaluation of serum Epstein–Barr virus DNA levels in 406 allogeneic stem cell transplant patients. Haematologica 2007; 92: 819–25.
9. Ocheni S., Kroeger N., Zabelina T. et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008; 43: 181–6.
10. Sundin M., Le Blanc K., Ringden O. et al. The role of HLA mismatch, splenectomy and recipient Epstein–Barr virus seronegativity as risk factors in posttransplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006; 91: 1059–67.
11. Curtis R. E., Travis L. B., Rowlings P. A. et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multiinstitutional study. Blood 1999; 94: 2208–16.
12. Van Esser J. W., van der Holt B., Meijer E. et al. Epstein–Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972–8.
13. Meijer E., Dekker A. W., Lokhorst H. M. et al. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 2004; 6: 171–8.
14. Chakrabarti S., Milligan D. W., Pillay D. et al. Reconstitution of the Epstein–Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003; 102: 839–42.
15. Snyder M. J., Stenzel T. T., Buckley P. J. et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol 2004; 28: 794–800.
16. Cohen J., Gandhi M., Naik P. et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005; 129: 229–39.
17. Meijer E. and Cornelissen J. J. Epstein–Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Current Opinion in Hematology 2008; 15: 576–85.
18. Meijer E., Dekker A. W., Weersink A. J. et al. Prevention and treatment of Epstein–Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants. Br J Haematol 2002; 119: 596–607.
19. Weinstock D. M., Ambrossi G. G., Brennan C. et al. Preemptive diagnosis and treatment of Epstein–Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006; 37: 539–46.
20. Wagner H. J., Wessel M., Jabs W. et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein–Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001; 72: 1012–9.
21. Dominetto A., Tedone E., Soracco M. et al. Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplant based on molecular monitoring is predictive of lymphoproliferative disease. Bone Marrow Transplantation. 2004; 33 (Suppl 1): 192.
22. Meerbach A., Wutzler P., Hafer R. et al. Monitoring of Epstein–Barr virus load after hematopoietic stem cell transplantation for early intervention in posttransplant lymphoproliferative disease. J Med Virol 2008; 80: 441–54.
23. Van Esser J. W., Niesters H. G., van der Holt B. et al. Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364–9.
24. Gustafsson A., Levitsky V., Zou J. Z. et al. Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T-cells. Blood 2000; 95: 807–14.
25. Cesaro S., Murrone A., Mengoli C. et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the preemptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005; 128: 224–33.
26. Wagner H. J., Cheng Y. C., Huls M. H. et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979–81.
27. Ljungman P. Prophylaxis against herpesvirus infections in transplant recipients. Drugs 2001; 61: 187–96.
28. Kuehnle I., Huls M. H., Liu Z. et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502–5.
29. Milpied N., Vasseur B., Parquet N. et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11 (Suppl 1): 113–6.
30. Faye A., Quartier P., Reguerre Y. et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in posttransplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112–8.
31. Choquet S., Leblond V., Herbrecht R. et al. Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053–7.
32. O’Reilly R. J., Small T. N., Papadopoulos E. et al. Biology and adoptive cell therapy of Epstein–Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997; 157: 195–216.
33. Lucas K. G., Burton R. L., Zimmerman S. E. et al. Semiquantitative Epstein–Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654–61.
Review
For citations:
Balashov D.N., Shelikhova L.N., Demushkina A.A., Trakhtman P.E., Skorobogatova Ye.V., Litvinov D.V., Raykina Ye.V., Maschan A.A. Epstein–Barr virus infection in patients after hematopoietic stem cells transplantation. Oncohematology. 2010;(3):59-64. (In Russ.)
Views:
252
Email this article 